Advertisement

Lipids in Health and Disease

, 17:230 | Cite as

The effects of coenzyme Q10 supplementation on lipid profiles among patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials

  • Mohammad Vahid Jorat
  • Reza Tabrizi
  • Naghmeh Mirhosseini
  • Kamran B. Lankarani
  • Maryam Akbari
  • Seyed Taghi Heydari
  • Reza Mottaghi
  • Zatollah Asemi
Open Access
Review

Abstract

Background

Chronic inflammation and increased oxidative stress significantly contribute in developing coronary artery disease (CAD). Hence, antioxidant supplementation might be an appropriate approach to decrease the incidence of CAD. This systematic review and meta-analysis was aimed to determine the effects of coenzyme Q10 (CoQ10) supplementation on lipid profile, as one of the major triggers for CAD, among patients diagnosed with coronary artery disease.

Methods

EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science were searched for studies prior to May 20th, 2018. Cochrane Collaboration risk of bias tool was applied to assess the methodological quality of included trials. I-square and Q-tests were used to measure the existing heterogeneity across included studies. Considering heterogeneity among studies, fixed- or random-effect models were applied to pool standardized mean differences (SMD) as overall effect size.

Results

A total of eight trials (267 participants in the intervention group and 259 in placebo group) were included in the current meta-analysis. The findings showed that taking CoQ10 by patients with CAD significantly decreased total-cholesterol (SMD -1.07; 95% CI, − 1.94, − 0.21, P = 0.01) and increased HDL-cholesterol levels (SMD 1.30; 95% CI, 0.20, 2.41, P = 0.02). We found no significant effects of CoQ10 supplementation on LDL-cholesterol (SMD -0.37; 95% CI, − 0.87, 0.13, P = 0.14), lipoprotein (a) [Lp(a)] levels (SMD -1.12; 95% CI, − 2.84, 0.61, P = 0.20) and triglycerides levels (SMD 0.01; 95% CI, − 0.22, 0.24, P = 0.94).

Conclusions

This meta-analysis demonstrated the promising effects of CoQ10 supplementation on lowering lipid levels among patients with CAD, though it did not affect triglycerides, LDL-cholesterol and Lp(a) levels.

Keywords

Coenzyme Q10 Lipid profiles Coronary artery disease Meta-analysis 

Abbreviations

HDL-C

high density lipoprotein-cholesterol

LDL-C

Low density lipoprotein-cholesterol

Lp(a)

Lipoprotein(a)

RCTs

Randomized controlled trials

TC

Total cholesterol

TG

Triglycerides

Background

Dyslipidemia is one of the major risk factor for establishing coronary artery disease (CAD) [1]. Coronary artery disease and cerebral stroke account for the main causes of morbidity and mortality among elderly and middle-aged individuals [2]. Cardiovascular risk factors are including aging, hyperglycemia and insulin resistance [3]. In addition, dyslipidemia, mainly hypercholesterolemia, high LDL-cholesterol, and low HDL-cholesterol levels [4] impair mitochondrial function, leading to increased production of free radicals and reactive oxygen species, and subsequently can result in chronic inflammation and endothelial dysfunction [5].

The damage of free radicals is proposed to play an important role in endothelial dysfunction and atherogenesis [6]. Coenzyme Q10 (CoQ10) is an intracellular antioxidant which prevents senescence and dysfunction caused by oxidative stress [6]. CoQ10 is commonly used to treat cardiomyopathy, and heart function has been remarkably improved following CoQ10 supplementation [7]. CoQ10 deficiency which usually occurs with aging have been shown to increase the risk of type 2 diabetes mellitus (T2DM) [8] and cardiovascular disease (CVD) [9]. On the other hand, there are trials evaluating the effects of CoQ10 on lipid profiles with inconclusive results. We have previously shown in a meta-analysis that taking CoQ10 by patients with metabolic disorders significantly reduced serum triglycerides levels, yet did not affect other lipid profiles [10]. In another meta-analysis conducted by Sahebkar et al. [11], CoQ10 supplementation significantly decreased lipoprotein (a) [Lp(a)] levels among patients with obesity, T2DM, and CVD, mainly in those with Lp(a) ≥ 30 mg/dL. However, in another meta-analysis conducted by Suksomboon et al. [12], CoQ10 supplementation had no beneficial effects on lipid profiles or blood pressures among diabetic patients.

Differences in study design, study population’s characteristics, the dosage of CoQ10 used and the duration of intervention might explain the discrepancies among current evidence. We are aware of no systematic review and meta-analysis of randomized controlled trials (RCTs) on the effect of CoQ10 supplementation on lipid profiles in patients with CAD. This meta-analysis was conducted to summarize the existing evidence of RCTs to evaluate the impact of CoQ10 supplementation on lipid profiles in patients with CAD.

Methods

PRISMA guideline (the preferred reporting items for systematic reviews and meta-analyses) was used to design and implement this meta-analysis.

Search strategy

Two independent authors (RT and MA) systematically searched online database including EMBASE, Scopus, PubMed, Cochrane Library, and Web of Science until 20th May 2018. Search words, including Mesh and text words, were applied as followed; (“chronic heart failure (CHF)” OR “CAD” OR “myocardial ischemia (MI)” OR “heart disease (HD)” OR “heart failure, diastolic” OR “CVD” OR “myocardial infarction (MI)” OR “acute myocardial infarction (AMI)” OR “cardiac disease (CD)” AND “Q10” OR “coenzyme Q10 (CoQ10)” OR “supplementation” OR “intake” AND “total cholesterol (TC)” “triglycerides (TG)” OR “low-density lipoprotein (LDL-cholesterol)” OR “LDL-C” OR “high-density lipoprotein (HDL-cholesterol)” OR “HDL-C” OR “lipoprotein(a) (Lp(a))”) to identify the relevant clinical trials examining the impact of CoQ10 supplementation on lipid profiles. To avoid missing any citation that had not been captured in the primary search, the reference lists of the relevant papers and the pervious article reviews were searched by the same two researchers (RT, MA). With no time restriction, clinical trials published in English were included in this meta-analysis.

Study selection

Two investigators (RT, MA) independently screened all studies, retrieved from the online database and hand-search, using a two-stage process in order to determine eligible studies for current meta-analysis. In the first stage, after reviewing the title and/or abstracts of the trials, any duplicate and non-relevant trial was removed from further process. Then, in the next stage, the full texts of related trials were retrieved to determine whether trials were potentially ideal for this meta-analysis, considering inclusion and exclusion criteria. Upon any disagreement, it was resolved by a discussion among themselves or with a third investigator (ZA or MV.J).

The following inclusion criteria was used to select eligible clinical trials for the meta-analysis: 1) being a human original RCT with parallel or crossover method; 2) study participants were patients diagnosed with heart diseases; 3) being a placebo-controlled clinical trial assessing the association between CoQ10 supplementation and lipid profiles; 4) clinical trials that reported the mean changes (SD or 95% CI) of the impact of CoQ10 on lipid profiles including total- and LDL-cholesterol, triglycerides, HDL-cholesterol, and Lp(a) at baseline and end of intervention in both intervention and placebo groups.

Animal or in-vitro trials, clinical trials without control groups, no RCT design, and any trial protocols, the congress abstracts without full text, and the studies did not meet the minimum requirement for quality assessment score were excluded from this meta-analysis.

Data extraction and quality assessment

The quality assessment and data extraction from each included trial were conducted by two independent investigators (RT and MA), using Cochrane Collaboration risk of bias tool and standard Excel sheet-form 2008, respectively. Any disagreement was discussed by a third investigator (ZA or MV.J).

The following study characteristics were used to assess the quality of included trials: “randomization generation, allocation concealment, blinding of participants and outcome assessors, incomplete outcome data, selective outcome reporting, and other sources of bias”. The following data was extracted from each clinical trial: first author’s name, year of publication, mean age, country of origin, study design, sample size (in intervention and placebo groups), duration of trial, dose of supplement, type of treatment and placebo in both intervention and control groups, the mean and SD/or 95% CI for total- and LDL-cholesterol, triglycerides, HDL-cholesterol, lipoprotein (a) concentrations at baseline and end of intervention in both intervention groups.

Statistical analyses

All statistical analyses were conducted using STATA version 12.0 (Stata Corp, College Station, TX) and Review Manager V.5.3 software (Cochrane Collaboration, Oxford, UK). The Cochran (Q) and I-squared statistics (I2) were applied to show the heterogeneity among included trials. Upon existing heterogeneity across trials (I2 ≥ 50% with P < 0.05), random effects model with DerSimonian and Laird method; otherwise, fixed-effect model with inverse variance method were used to calculate the standardized mean differences (SMDs) with 95% CI considering as the pool effect size. Further, subgroup analyses were used based on pre-defined criteria such as type of disease (HF vs. CAD), type of intervention (Q10 vs. Q10 plus other nutrients), dosage of supplement (≤ 150 vs. > 150 mg/day), duration of trial (< 8 weeks vs. ≥8 weeks), and sample size (≤50 vs. > 50 individuals in intervention groups) to identify the source of heterogeneity based on confounding variables.

Sensitivity analyses were conducted to specify the effect of each included trial on the pooled SMDs, using leave-one-out method. Egger’s and Begg’s tests were used to indicate the potential publication bias for the outcome measures. P < 0.05 was considered as statistically significant.

Results

A total of 814 studies were identified though our initial literatures search. After screening RCTs, 8 studies were determined to be appropriate for in the present meta-analysis. The flow diagram of step by step studies identification and selection has been illustrated in Fig. 1. Seven clinical trials had double-blinded design and one of the trials was single-blinded. Seven trials were conducted using parallel design and one cross-over design. Eight RCTs reported the effects of CoQ10 supplementation on total cholesterol, 6 on LDL-cholesterol, 4 on triglycerides, 5 on HDL-cholesterol, and 3 on Lp(a). Sample size varied from 21 to 73 participants with an overall number of 267 subjects. The sample size in the placebo group was ranged from 21 to 71 with an overall number of 259 subjects. Duration of the intervention among included trials was ranged from 4 to 48 weeks. The detailed characteristics of included trials were summarized in Table 1. The assessment of the methodological quality of the included trials has been indicated in Fig. 2. The findings of risk of bias assessment indicated that 6 studies were at unclear risk of bias, and 2 studies were at high risk bias based on the judgments of author.
Fig. 1

Literature search and review flowchart for selection of studies

Table 1

Characteristics of included studies

Authors (Ref)

Publication year

Sample size (control/intervention)

Country/population

Intervention (name and daily dose)

Duration

Age (control, intervention)

Presented data

Belardinelli et al. [23]

2006

21/21

Italy/chronic HF

CoQ10 100 mg/day

4 weeks

60 ± 8

TC, LDL-C, TG, HDL-C

Dai Y et al. [24]

2011

28/28

Hong Kong/left ventricular systolic dysfunction

CoQ10 300 mg/ day

8 weeks

65.9 ± 12.5, 59.9 ± 13.1

TC, LDL-C, HDL-C, Lp(a)

Mohseni et al. [15]

2015

26/26

Iran/acute myocardial infarction

CoQ10 200 mg/day

12 weeks

48.4 ± 0.5, 47.6 ± 0.3

TC, LDL-C, TG, HDL-C

Mirhashemi et al. [25]

2016

30/30

Iran/T2DM with CAD

CoQ10 100 mg/day

8 weeks

68.9 ± 9.6

Lp(a)

Pourmoghaddas M et al. [26]

2013

30/32

Iran/statin treated coronary heart failure patients

CoQ10 200 mg/ day

16 weeks

48.0 ± 8.6, 47.6 ± 8.2

TC, LDL-C

Singh et al. [19]

1999

22/25

India/CAD

CoQ10 120 mg/day

4 weeks

50.70 ± 12.5, 54.47 ± 14.6

TC, LDL-C, HDL-C, Lp(a)

Singh et al. [14]

2003

71/73

India/myocardial infarction

CoQ10 120 mg/day

48 weeks

51 ± 9,

51 ± 10

TC, LDL-C, TG, HDL-C

Sharifi et al. [13]

2017

31/32

Iran/myocardial infarction

CoQ10 150 mg/day and L-carnitine 1200 mg/day

3 months

59 ± 9

TC

CAD coronary artery disease, HDL-C high density lipoprotein-cholesterol, HF heart failure, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein(a), TC total cholesterol, TG triglycerides, T2DM type 2 diabetes mellitus

Fig. 2

The summary of review authors’ judgments about each risk of bias item for each included study

Effects of CoQ10 on lipid profiles

Using random-effect model, the pooled results for lipid profiles showed that CoQ10 supplementation significantly decreased total cholesterol (SMD -1.07; 95% CI, − 1.94, − 0.21, P = 0.01; I2 = 94.9%) and increased HDL-cholesterol levels (SMD 1.30; 95% CI, 0.20, 2.41, P = 0.02; I2 = 94.7%). We found no significant impact of CoQ10 supplementation on LDL-cholesterol (SMD -0.37; 95% CI, − 0.87, 0.13, P = 0.14; I2 = 82.8%) and Lp(a) (SMD -1.12; 95% CI, − 2.84, 0.61, P = 0.20; I2 = 95.7%), using random-effect model and triglycerides levels (SMD 0.01; 95% CI, − 0.22, 0.24, P = 0.940; I2 = 0.00%), using fixed-effect model (Fig. 3).
Fig. 3

A-E. Meta-analysis lipid profiles standardized mean differences estimates for (a) total cholesterol, b for LDL-cholesterol, c for triglycerides, d for HDL-cholesterol and (e) for lipoprotein(a) in CoQ10 and control groups (CI = 95%).Total SS, total sample size

The detailed results of meta-analyses for the effects of CoQ10 on lipid profiles including total- and LDL-cholesterol, triglycerides, HDL-cholesterol, lipoprotein(a) concentrations at baseline and end of the trial in both intervention and placebo groups have been presented in Table 2.
Table 2

Estimation of the effects of CoQ10 supplementation on lipid profiles at baseline and the end of the treatment between intervention and placebo groups

Variable

Number of study

Standardized Mean difference

CI 95%

P-value

Heterogeneity

I2 (%)

Q

P-value Heterogeneity

TC

Intervention group (after vs. before)

7

-1.07

−1.88, − 0.26

0.009

93.7

95.40

< 0.001

Placebo group (after vs. before)

7

−0.37

− 0.56, − 0.19

< 0.001

42.0

10.34

0.11

Change intervention group vs. placebo group

8

−1.07

−1.94, − 0.21

0.015

94.9

138.32

< 0.001

LDL-C

Intervention group (after vs. before)

5

−0.71

−1.30, − 0.12

0.019

84.8

26.27

< 0.001

Placebo group (after vs. before)

5

−0.55

−1.21, 0.10

0.098

87.3

31.60

< 0.001

Change intervention group vs. placebo group

6

−0.37

−0.87, 0.13

0.149

82.8

29.05

< 0.001

TG

Intervention group (after vs. before)

3

0.15

−0.38, 0.68

0.591

71.6

7.04

0.03

Placebo group (after vs. before)

3

−0.09

−0.34, 0.17

0.493

0.00

0.31

0.85

Change intervention group vs. placebo group

4

0.01

−0.22, 0.24

0.940

0.00

2.93

0.40

HDL-C

Intervention group (after vs. before)

4

0.54

−0.07, 1.16

0.081

82.3

16.93

0.001

Placebo group (after vs. before)

4

−0.01

− 0.24, 0.23

0.964

0.00

0.35

0.95

Change intervention group vs. placebo group

5

1.30

0.20, 2.41

0.021

94.7

76.05

< 0.001

Lp(a)

Intervention group (after vs. before)

2

− 0.71

− 1.91, 0.50

0.252

89.1

9.19

0.002

Placebo group (after vs. before)

2

0.02

−0.37, 0.40

0.929

0.00

0.17

0.68

Change intervention group vs. placebo group

3

−1.12

−2.84, 0.61

0.204

95.7

46.96

< 0.001

HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein (a); TC total cholesterol, TG triglycerides

The findings of sensitivity analyses revealed that pooled SMDs for the impact of CoQ10 on LDL-cholesterol and triglycerides were robust, and removing each trial did not affect the overall results of meta-analysis. Further, the pooled SMDs for total cholesterol was significantly different between the pre- (− 1.07; 95% CI, − 1.94, − 0.21) and post-sensitivity pooled SMD (− 0.26; 95% CI, − 0.72, 0.18) after removing Sharifi et al. [13]. For HDL-cholesterol also, the pre- (1.30; 95% CI, 0.20, 2.41) and post-sensitivity pooled SMD were significantly different after excluding Singh et al. [14] (1.41; 95% CI, − 0.20, 3.03) and Mohseni et al. [15] (0.47; 95% CI, − 0.13, 1.09) (Table 3).
Table 3

The assess of contribution each clinical trials in association between CoQ10 supplementation and lipid profiles based on sensitivity analysis

Variable

Pre-sensitivity analysis

Upper & lower of effect size

Post-sensitivity analysis

No. of studies included

Pooled SMD (random effect)

95% CI

Pooled SMD (random effect)

95% CI

Excluded studies

TC

8

−1.07

− 1.94, − 0.21

Upper

−0.26

− 0.72, 0.18

Sharifi (b)

Lower

−1.30

−2.29, −0.31

Dai Y

LDL-C

6

−0.37

−0.87, 0.13

Upper

−0.14

− 0.42, 0.12

Pourmoghaddas

Lower

−0.48

− 1.04, 0.06

Belardinelli

TG

4

0.01

−0.22, 0.24

Upper

0.16

−0.15, 0.48

Singh (2003)

Lower

−0.05

− 0.30, 0.19

Belardinelli

HDL-C

5

1.30

0.20, 2.41

Upper

1.67

0.32, 3.03

Dai Y

Lower

0.47

−0.13, 1.09

Mohseni

Lp(a)

3

−1.12

−2.84, 0.61

Upper

− 0.03

−0.39, 0.33

Singh (1999)

Lower

−1.79

−4.98, 1.40

Manolescu

HDL-C high density lipoprotein-cholesterol, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein (a); TC total cholesterol, TG triglycerides

Considering type of disease, the results of subgroup analysis showed a significant reduction in total cholesterol concentrations among patients with CAD (SMD -2.01; 95% CI, − 3.43, − 0.60) rather than those with HF (SMD 0.16; 95% CI, − 0.15, 0.47). Trials applying dosages ≤150 mg/day indicated greater reduction in total cholesterol levels (SMD -1.53; 95% CI, − 2.83, − 0.23) compared with the dosage of intervention > 150 mg/day (SMD -0.52; 95% CI, − 1.78, 0.73). Moreover, compared with trials shorter than 8 weeks, total cholesterol concentrations showed greater reduction in trials with ≥8 weeks’ supplementation (0.06 vs. -1.94, 95% CI: -3.33, − 0.54) (Table 4). LDL-cholesterol and Lp(a) levels did not show any significant difference applying potential moderators in subgroup analyses (Table 4).
Table 4

The effects of CoQ10 supplementation on lipid profiles with CI 95% by using subgroup analysis

Variables

Ka

I2 (%)

Q test

SMD (95% CI)

P-value

TC

 Total

8

94.9

138.32

−1.07 (−1.94, −0.21)

0.015

 Type of disease

  HF

3

0.00

0.04

0.16 (−0.15, 0.47)

0.306

  CAD

5

96.7

122.87

−2.01 (−3.43, −0.60)

0.005

 Type of intervention

  Q10

6

84.7

32.72

−0.32 (−0.85, 0.22)

0.244

  Q10 + other

2

99.0

102.67

−4.50 (−13.39, 4.39)

0.321

 Dosage of intervention (mg/dL)

   ≤ 150

5

96.3

107.92

−1.53 (−2.83, −0.23)

0.021

   > 150

3

93.4

30.37

−0.52 (−1.78, 0.73)

0.414

 Duration of study

   < 8 weeks

3

0.00

1.06

0.06 (−0.26, 0.39)

0.707

   ≥ 8 weeks

5

96.9

128.76

−1.94 (−3.33, − 0.54)

0.006

 Sample size

   ≤ 50 person

2

0.00

0.60

−0.03 (− 0.44, 0.39)

0.13

   > 50 person

6

96.3

135.05

−1.52 (−2.67, − 0.37)

2.59

LDL-C

 Total

6

82.8

29.05

−0.37 (− 0.87, 0.13)

0.149

 Type of disease

  HF

3

91.8

24.47

−0.51 (−1.66, 0.64)

0.387

  CAD

3

42.7

3.49

−0.25 (− 0.61, 0.11)

0.167

 Type of intervention

  Q10

6

82.8

29.05

−0.37 (− 0.87, 0.13)

0.149

  Q10 + other

 Dosage of intervention

   ≤ 150

3

48.7

3.90

−0.24 (− 0.64, 0.16)

0.232

   > 150

3

91.8

24.25

−0.53 (−1.64, 0.57)

0.344

 Duration of study

   < 8 weeks

3

40.5

3.36

−0.12 (− 0.55, 0.30)

0.568

   ≥ 8 weeks

3

91.2

22.64

−0.62 (−1.55, 0.31)

0.195

 Sample size

   ≤ 50 person

2

70.0

3.33

−0.14 (− 0.91, 0.63)

0.721

   > 50 person

4

87.8

24.52

−0.48 (−1.17, 0.21)

0.171

HDL-C

 Total

 Type of disease

5

94.7

76.05

1.30 (0.20, 2.41)

0.021

  HF

2

0.00

0.02

−0.04 (−0.43, 0.36)

0.859

  CAD

3

95.9

48.48

2.28 (0.51, 4.05)

0.011

 Type of intervention

  Q10

5

94.7

76.05

1.30 (0.20, 2.41)

0.021

  Q10 + other

 Dosage of intervention

   ≤ 150

3

78.5

9.29

0.66 (0.03, 1.30)

0.041

   > 150

2

98.5

66.76

2.58 (−2.65, 7.81)

0.334

 Duration of study

   < 8 weeks

3

62.7

5.36

0.24 (−0.30, 0.78)

0.387

   ≥ 8 weeks

2

97.8

45.29

3.14 (−0.96, 7.24)

0.133

 Sample size

   ≤ 50 person

2

71.2

3.48

0.41 (−0.39, 1.20)

0.315

   > 50 person

3

97.0

67.48

2.00 (0.06, 3.93)

0.043

Lp(a)

 Total

3

95.7

46.96

−1.12 (−2.84, 0.61)

0.204

 Type of disease

  HF

1

0.00

0.13 (−0.39, 0.66)

0.621

  CAD

2

97.3

37.38

−1.79 (−4.98, 1.40)

0.272

 Type of intervention

  Q10

3

95.7

46.96

−1.12 (−2.84, 0.61)

0.204

  Q10 + other

 Dosage of intervention

   ≤ 150

2

97.3

37.38

−1.79 (− 4.98, 1.40)

0.272

   > 150

1

0.00

0.13 (−0.39, 0.66)

0.621

 Duration of study

   < 8 weeks

2

97.7

44.27

−1.64 (−5.14, 1.87)

0.360

   ≥ 8 weeks

1

0.00

−0.18 (− 0.69, 0.32)

0.476

 Sample size

   ≤ 50 person

1

0.00

−3.44 (−4.36, −2.53)

< 0.001

   > 50 person

2

0.00

0.72

−0.03 (− 0.40, 0.33)

0.866

a K, Number of SMD included; CAD coronary artery disease, HDL-C high density lipoprotein-cholesterol, HF heart failure, LDL-C low density lipoprotein-cholesterol, Lp(a) Lipoprotein(a), TC total cholesterol

CoQ10 supplementation significantly increased HDL-cholesterol concentrations in patients with CVD (SMD 2.28; 95% CI, 0.51, 4.05) rather than those with HF (SMD -0.04; 95% CI, − 0.43, 0.36). Considering the dosage of intervention, subgroup analysis revealed that CoQ10 doses ≤150 mg/day significantly increased HDL-cholesterol concentrations (SMD 0.66; 95% CI, 0.03, 1.30) rather than doses of > 150 mg/day intervention (SMD 2.58; 95% CI, − 2.65, 7.81). Further, with the total sample size > 50 participants, HDL-cholesterol levels were significantly higher (SMD 2.00; 95% CI, 0.06, 3.93) when compared to trials with ≤50 participants (SMD 0.41; 95% CI, − 0.39, 1.20). The detailed results of subgroup analyses have been summarized in Table 4.

Publication bias

Begg’s and Egger’s statistics indicated no significant evidence of publication bias for the meta-analyses evaluating the effects of CoQ10 on total cholesterol (Begg’s: Z = − 0.99, P = 0.32 and Egger’s: B = − 8.96, P = 0.05), LDL-cholesterol (Begg’s: Z = 0.19, P = 0.85 and Egger’s: B = − 0.51, P = 0.91), triglycerides (Begg’s: Z = 1.07, P = 0.08 and Egger’s: B = 2.99, P = 0.10), HDL-cholesterol (Begg’s: Z = 0.49, P = 0.62 and Egger’s: B = 5.31, P = 0.43), and Lp (a) (Begg’s: Z = 0.52, P = 0.60 and Egger’s: B = − 7.28, P = 0.50).

Discussion

The findings of current systematic review and meta-analysis showed that CoQ10 supplementation significantly improved lipid profiles by decreasing total cholesterol and increasing HDL-cholesterol levels, though did not affect triglycerides, LDL-cholesterol and Lp(a) levels in patients with CAD.

CoQ10 deficiency usually occurs with aging and may increase the risk of CVD [9, 16, 17]. We have previously demonstrated in another meta-analysis that taking CoQ10 by patients with metabolic disorders significantly reduced serum triglycerides levels, yet did not affect other lipid profiles [10]. Meta-analysis conducted by Pirro et al. [18] showed that taking a nutraceutical combination of red yeast rice, berberine, policosanol, astaxanthin, CoQ10 and folic acid significantly reduced serum triglycerides, total-, LDL-and HDL-cholesterol levels. Supplementation with 200 mg/day CoQ10 for 12 weeks significantly increased HDL-cholesterol levels in hyperlipidemic patients with myocardial infarction, though did not affect other parameters of lipid profiles [15]. Supplementation with 120 mg/day CoQ10 for 28 days led to similar results among patients with acute coronary disease [19]. In a meta-analysis conducted by Suksomboon et al. [12], total cholesterol levels significantly decreased after taking CoQ10 plus fenofibrate. The anti-hyperlipidemic effect of fenofibrate has already been proven; though its synergistic impact with CoQ10 is promising. Significant reduction in serum triglyceride levels was reported following supplementation with CoQ10 plus fenofibrate [12]. However, Sahebkar et al. [11] documented in their meta-analysis that CoQ10 supplementation significantly decreased plasma Lp(a) levels in individuals with lipoprotein a [Lp(a)] ≥30 mg/dL, though other lipid profiles parameters remained unchanged. In addition, CoQ10 administration to diabetic patients had no beneficial effects on lipid profiles and blood pressure [12].

The type and different dosages of CoQ10 used are some of the possible reasons that might explain the discrepant results among previous published studies. Although the main reason CoQ10 affects lipid profiles is unknown; several mechanisms have been proposed by which CoQ10 supplements could improve lipid profiles. As an intracellular antioxidant, CoQ10 protects the cell membrane phospholipids and mitochondrial membrane protein against free radical-induced damage [6]. Aldehyde derivatives from lipid peroxidation, such as malondialdehyde, inhibit lecithin-cholesterol acyl transferase (LCAT), which esterifies free cholesterol on HDL-cholesterol. So, CoQ10 can promote HDL-cholesterol production, suppress oxidative stress and subsequently reduce malondialdehyde levels [20]. In addition, CoQ10 ingestion may induce gene expression of peroxisome proliferator-activated receptor-γ (PPAR-γ) through activating calcium-mediated AMPK pathway and inhibiting differentiation-induced adipogenesis [21]. PPAR-γ is a nuclear receptor protein which acts as a ligand-activated transcription factor in regulating gene expression affecting insulin and lipid metabolism, differentiation, proliferation, survival and inflammation [22].

Conclusions

CoQ10 supplementation significantly improved some of the parameters of lipid profile including total cholesterol and HDL-cholesterol levels in patients with CAD, though it might not affect the other parameters of lipid profiles. Additional prospective studies regarding the effect of CoQ10 intake on lipid profiles in patients with CAD are necessary.

Notes

Acknowledgements

The present study was supported by a grant from the Vice-chancellor for Research, SUMS, Shiraz, and Iran.

Funding

The present study was founded by a grant from the Vice Chancellor for Research, Shiraz University of Medical Sciences, in Iran.

Availability of data and materials

The primary data for this study is available from the authors on direct request.

Authors’ contributions

ZA contributed in conception, design, statistical analysis and drafting of the manuscript. RT, VO, KL, PP, MA and FK contributed in data collection and manuscript drafting. All authors approved the final version for submission. ZA supervised the study.

Ethics approval and consent to participate

This study was considered exempt by the SUMS Institutional Review Board.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Liu HH, Li JJ. Aging and dyslipidemia: a review of potential mechanisms. Ageing Res Rev. 2015;19:43–52.CrossRefGoogle Scholar
  2. 2.
    Pisciotta L, Bertolini S, Pende A. Lipoproteins, stroke and statins. Curr Vasc Pharmacol. 2015;13:202–8.CrossRefGoogle Scholar
  3. 3.
    Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–90.CrossRefGoogle Scholar
  4. 4.
    Knight-Lozano CA, Young CG, Burow DL, Hu ZY, Uyeminami D, Pinkerton KE, et al. Cigarette smoke exposure and hypercholesterolemia increase mitochondrial damage in cardiovascular tissues. Circulation. 2002;105:849–54.CrossRefGoogle Scholar
  5. 5.
    Madamanchi NR, Runge MS. Mitochondrial dysfunction in atherosclerosis. Circ Res. 2007;100:460–73.CrossRefGoogle Scholar
  6. 6.
    Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev. 2007;65:286–93.CrossRefGoogle Scholar
  7. 7.
    Mortensen SA. Overview on coenzyme Q10 as adjunctive therapy in chronic heart failure. Rationale, design and end-points of "Q-symbio"--a multinational trial. Biofactors. 2003;18:79–89.CrossRefGoogle Scholar
  8. 8.
    Shen Q, Pierce JD. Supplementation of coenzyme Q10 among patients with type 2 diabetes mellitus. Healthcare (Basel). 2015;3:296–309.CrossRefGoogle Scholar
  9. 9.
    Niklowitz P, Sonnenschein A, Janetzky B, Andler W, Menke T. Enrichment of coenzyme Q10 in plasma and blood cells: defense against oxidative damage. Int J Biol Sci. 2007;3:257–62.CrossRefGoogle Scholar
  10. 10.
    Sharifi N, Tabrizi R, Moosazadeh M, Mirhosseini N, Lankarani KB, Akbari M, et al. The effects of coenzyme Q10 supplementation on lipid profiles among patients with metabolic diseases: a systematic review and meta-analysis of randomized controlled trials. Curr Pharm Des. 2018.  https://doi.org/10.2174/1381612824666180406104516 [Epub ahead of print].
  11. 11.
    Sahebkar A, Simental-Mendia LE, Stefanutti C, Pirro M. Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: a systematic review and meta-analysis. Pharmacol Res. 2016;105:198–209.CrossRefGoogle Scholar
  12. 12.
    Suksomboon N, Poolsup N, Juanak N. Effects of coenzyme Q10 supplementation on metabolic profile in diabetes: a systematic review and meta-analysis. J Clin Pharm Ther. 2015;40:413–8.CrossRefGoogle Scholar
  13. 13.
    Sharifi MH, Eftekhari MH, Ostovan MA, Rezaianazadeh A. Effects of a therapeutic lifestyle change diet and supplementation with Q10 plus L-carnitine on quality of life in patients with myocardial infarction: a randomized clinical trial. J Cardiovasc Thorac Res. 2017;9:21–8.CrossRefGoogle Scholar
  14. 14.
    Singh RB, Neki NS, Kartikey K, Pella D, Kumar A, Niaz MA, et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem. 2003;246:75–82.CrossRefGoogle Scholar
  15. 15.
    Mohseni M, Vafa M, Zarrati M, Shidfar F, Hajimiresmail SJ, Rahimi FA. Beneficial effects of coenzyme Q10 supplementation on lipid profile and Intereukin-6 and intercellular adhesion Molecule-1 reduction, Preliminary Results of a Double-blind Trial in Acute Myocardial Infarction. Int J Prev Med. 2015;6:73.CrossRefGoogle Scholar
  16. 16.
    Flowers N, Hartley L, Todkill D, Stranges S, Rees K. Co-enzyme Q10 supplementation for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;12:Cd010405.  https://doi.org/10.1002/14651858.CD010405.pub2.
  17. 17.
    Nukui K, Yamagishi T, Miyawaki H, Kettawan A, Okamoto T, Belardinelli R, et al. Blood CoQ10 levels and safety profile after single-dose or chronic administration of PureSorb-Q40: animal and human studies. Biofactors. 2008;32:209–19.CrossRefGoogle Scholar
  18. 18.
    Pirro M, Mannarino MR, Bianconi V, Simental-Mendia LE, Bagaglia F, Mannarino E, et al. The effects of a nutraceutical combination on plasma lipids and glucose: a systematic review and meta-analysis of randomized controlled trials. Pharmacol Res. 2016;110:76–88.CrossRefGoogle Scholar
  19. 19.
    Singh RB, Niaz MA. Serum concentration of lipoprotein(a) decreases on treatment with hydrosoluble coenzyme Q10 in patients with coronary artery disease: discovery of a new role. Int J Cardiol. 1999;68:23–9.CrossRefGoogle Scholar
  20. 20.
    McCall MR, Tang JY, Bielicki JK, Forte TM. Inhibition of lecithin-cholesterol acyltransferase and modification of HDL apolipoproteins by aldehydes. Arterioscler Thromb Vasc Biol. 1995;15:1599–606.CrossRefGoogle Scholar
  21. 21.
    Lee SK, Lee JO, Kim JH, Kim N, You GY, Moon JW, et al. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARalpha induction in 3T3-L1 preadipocytes. Cell Signal. 2012;24:2329–36.CrossRefGoogle Scholar
  22. 22.
    Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res. 2006;45:120–59.CrossRefGoogle Scholar
  23. 23.
    Belardinelli R, Mucaj A, Lacalaprice F, Solenghi M, Seddaiu G, Principi F, et al. Coenzyme Q10 and exercise training in chronic heart failure. Eur Heart J. 2006;27:2675–81.CrossRefGoogle Scholar
  24. 24.
    Dai YL, Luk TH, Yiu KH, Wang M, Yip PM, Lee SW, et al. Reversal of mitochondrial dysfunction by coenzyme Q10 supplement improves endothelial function in patients with ischaemic left ventricular systolic dysfunction: a randomized controlled trial. Atherosclerosis. 2011;216:395–401.CrossRefGoogle Scholar
  25. 25.
    Mirhashemi SM, Najafi V, Raygan F, Asemi Z. The effects of coenzyme Q10 supplementation on cardiometabolic markers in overweight type 2 diabetic patients with stable myocardial infarction: a randomized, double-blind, placebo-controlled trial. ARYA Atheroscler. 2016;12:158–65.PubMedPubMedCentralGoogle Scholar
  26. 26.
    Pourmoghaddas M, Rabbani M, Shahabi J, Garakyaraghi M, Khanjani R, Hedayat P. Combination of atorvastatin/coenzyme Q10 as adjunctive treatment in congestive heart failure: a double-blind randomized placebo-controlled clinical trial. ARYA Atheroscler. 2014;10:1–5.PubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Cardiovascular Research CenterShiraz University of Medical SciencesShirazIran
  2. 2.Health Policy Research Center, Institute of Health, Student Research CommitteeShiraz University of Medical SciencesShirazIran
  3. 3.School of Public HealthUniversity of SaskatchewanSaskatoonCanada
  4. 4.Health Policy Research Center, Institute of HealthShiraz University of Medical SciencesShirazIran
  5. 5.Research Center for Biochemistry and Nutrition in Metabolic DiseasesKashan University of Medical SciencesKashanIran

Personalised recommendations